The therapeutic use of anti-IGF-2 neutralizing antibodies may offer better tolerability by avoiding hyperglycemia, a common side effect of small molecule IGF1R inhibitors, due to cross-reaction with the Insulin Receptor. The gene discussed is IGF1R; the disease is Hyperglycemia.